Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: There is a need for high quality evidence on the adverse effects of medical interventions to inform policy, practice and research. Methods to systematically review adverse effects have not been fully developed. We aimed to assess the current methods and reporting used by such reviews. Methods: Survey of general medical, drug safety and pharmacology journals published in 2006. Methods including: searching, inclusion criteria, quality assessment and meta‐analysis were assessed. Results: Forty three systematic reviews from 2704 abstracts in 16 journals were included. The search strategy was not reported by 10 (23%) of reviews. The collection and reporting of the adverse effects from primary studies was described by 4/37 (12%) reviews and the quality of included studies was assessed by 15 (35%) of reviews. Meta‐analysis on rare outcomes and handing of zero event data were inconsistent. A polarity in the standard of reporting between reviews was observed. The reporting standard we found was similar to another survey of systematic reviews. Conclusion: Reporting was poor with respect to searching and definition/collection of adverse effects and guidelines such as QUOROM and MOOSE could be employed by authors. Comprehensive and clear reporting should be enforced by journals. The low proportion of reviews assessing quality, and the inconsistencies observed when modelling rare event data reflect the need for empirical research to underpin methods in these areas. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040297 · Cited by 8,613
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“Meta-analysing rare adverse event data is an important issue, as has been highlighted in a controversial study.(12) The issues with meta-analysis of rare event data include: what statistical model should be used, how to test for heterogeneity, what to do when no events are observed and whether to include only those tr…”
MethodVandenbroucke, J. P., Elm, E. V., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010-w1 · Cited by 3,543
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907 · cited 2×
“Quality assessment is important because poor methodological quality can lead to an alteration in the estimates of harm.(24,34) However, there is a lack of standardised guidelines for assessing the quality of studies with respect to adverse effects.”
BackgroundMethodWhat to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734 · cited 2×
“5 is used in order to include the study in the overall pooled estimate (of a relative measure), however this does not perform well if the group has an uneven number of subjects.(30) Of the 11 reviews which had zero events in a single arm, four reported which continuity correction was used.”
BackgroundMethodMuch ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938 · cited 2×
“Bradburn et al.(44) found the least biased estimate for rare event data was the Peto odds ratio method, and the most biased methods were the inversevariance, DerSimonian & Laird, and Mantel-Haenszel (MH) method when using a 0.”
MethodInfluentialWhen are observational studies as credible as randomised trials?
Vandenbroucke, J. P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16261-2 · Cited by 538 · cited 1×
“It is recognised that clinical trials designed to assess efficacy may not provide the best evidence for rare, unexpected or long term adverse effects.(2,42,43) In our survey we found that just under half of studies included information from observational studies, case reports or spontaneous reports.”
BackgroundJadad, A. R., Cook, D. J., Jones, A., Klassen, T. P., Tugwell, P., Moher, M., & Moher, D. (1998) · JAMA · doi:10.1001/jama.280.3.278 · Cited by 534
Systematic reviews of adverse effects: framework for a structured approach
Loke, Y. K., Price, D., Herxheimer, A., & the Cochrane Adverse Effects Methods Group (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-32 · Cited by 253
Shuster, J. J., Jones, L. S., & Salmon, D. A. (2007) · Statistics in Medicine · doi:10.1002/sim.3060 · Cited by 105
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Completeness of Safety Reporting in Randomized Trials: An Evaluation of 7 Medical Areas
Ioannidis, J. P. A., & Lau, J. (2001) · JAMA · doi:10.1001/jama.285.4.437 · Cited by 3
Cited by
PRISMA harms checklist: improving harms reporting in systematic reviews
Zorzela, L., Loke, Y. K., Ioannidis, J. P., Golder, S., Santaguida, P., Altman, D. G., Moher, D., Vohra, S., & PRISMA harms group (2016) · BMJ · doi:10.1136/bmj.i157 · Cited by 557
Quality of reporting in systematic reviews of adverse events: systematic review
Zorzela, L., Golder, S., Liu, Y., Pilkington, K., Hartling, L., Joffe, A., Loke, Y., & Vohra, S. (2014) · BMJ · doi:10.1136/bmj.f7668 · Cited by 217
Koffel, J. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125931 · Cited by 159
Harms in Systematic Reviews Paper 1: An introduction to research on harms
Qureshi, R., Mayo-Wilson, E., & Li, T. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.10.023 · Cited by 63
Metadata
- Authors
- Cornelius, V. R., Perrio, M. J., Shakir, S. A. W., & Smith, L. A.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2009-09-15
- Volume
- 18
- Issue
- 12
- Pages
- 1223-1231
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W1980680565
- Cited by
- 54
- References
- 12
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.